During pandemic situations, the adjuvants may play a critical role in reducing the dose requirement to induce protective immunity in subjects, thereby allowing more people to be vaccinated with limited supply. In this study, a dose-sparing effect afford by squalene-based adjuvant was evaluated by reducing the vaccine dose ranging from 3 μg to

0.004 μg. All of the formulations attained an adequate immune response, achieved theoretically protective HAI titers against H7N9 in mice, and afford substantial cross-reactive HAI titers against H7N7 viral selleck chemical strain (Fig. 5A–D). To further address the vaccine potency, we also evaluate the protection efficacy

in animals. As the humoral immune response induced by AddaVAX-adjuvanted H7N9 vaccines have reached plateau level at the doses of 1.5 μg and above (Fig. 5, lanes F, G, L, and M), the protection of mice see more against virus challenge were only investigated at the doses of 0.5 μg or less. Virus challenge result showed that 0.5 μg or lower dose (0.004–0.1 μg) of AddaVAX-adjuvanted H7N9 split vaccine were sufficient to provide 100% protection from death in mice (Fig. 6A). However, the group of mice vaccinated with lower dose of H7N9-AddaVAX split vaccines exhibited an dramatically body weight loss (more than 20% of body weight change) in Libraries contrast to the mice group receiving 0.5 μg AddaVAX-H7N9 split vaccine (Fig. 6B). This result is consistent with that the 0.5 μg AddaVAX-H7N9 Mannose-binding protein-associated serine protease split vaccine exhibited significantly

predominant immune response against H7N9 virus compared with lower-dose groups (Fig. 5A and B, lane E vs. lanes A–D). All above evidences indicate the squalene-based adjuvantation is a promising way to prepare for effective H7N9 vaccine for surged demand. Accordingly, we highlight that 0.5 μg AddaVAX-H7N9 split virus vaccine is the optimal formulation relevant to providing potent immune response to cross-reaction with H7N7 virus and better protection of mice against H7N9 challenge. Our results also showed that Al(OH)3 can modestly enhance the H7-subtype antigens immunogenicity to move the dose-response curve to lower antigen concentration and works slightly better with high-dose of whole virus (Fig. 2A, lane H vs. b (p < 0.05) and Fig. 4A, lane E vs. Q (p < 0.05)) while the squalene-based adjuvant shifts the optimum immunogenic dose of H7N9 split vaccine at least 10-fold lower ( Fig. 5) and could be proven experimentally in a mouse model. This phenomenon of squalene-based adjuvant enhancing the immune response of poorly immunogenic split antigen is in line with the observation of previous pre-clinical and clinical studies.